HoxC6 Antibody (B-7): sc-376330

HoxC6 Antibody (B-7) is a mouse monoclonal IgG2a kappa light chain antibody that detects HoxC6 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-HoxC6 antibody (B-7) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. HoxC6 protein plays a crucial role in embryonic development and cellular differentiation by regulating downstream target gene expression, which is essential for establishing the anterior-posterior body axis. HoxC6 functions as a sequence-specific transcription factor that influences DNA-protein and protein-protein interactions, thereby guiding morphogenetic processes that define structural organization of developing tissues. The mammalian HOX gene complex, which includes HoxC6, consists of 39 genes distributed across four linkage groups on four chromosomes, with trans-paralogous genes exhibiting greater similarity in sequence and expression patterns than their adjacent counterparts. This intricate regulatory system provides positional identities to cells and highlights HoxC6 as a novel therapeutic target in conditions such as prostate cancer, where dysregulation may contribute to tumorigenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HoxC6 Antibody (B-7) References:

1. Enhancer timing of Hox gene expression: deletion of the endogenous Hoxc8 early enhancer.  |  Juan, AH. and Ruddle, FH. 2003. Development. 130: 4823-34. PMID: 12917291
2. Aberrant HOXC expression accompanies the malignant phenotype in human prostate.  |  Miller, GJ., et al. 2003. Cancer Res. 63: 5879-88. PMID: 14522913
3. Loss of HOXC6 expression induces apoptosis in prostate cancer cells.  |  Ramachandran, S., et al. 2005. Oncogene. 24: 188-98. PMID: 15637592
4. Expression of 11 HOX genes is deregulated in esophageal squamous cell carcinoma.  |  Chen, KN., et al. 2005. Clin Cancer Res. 11: 1044-9. PMID: 15709170
5. Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells.  |  Singleton, DW., et al. 2006. Environ Res. 100: 86-92. PMID: 16029874
6. Analysis of single nucleotide polymorphisms and haplotypes in HOXC gene cluster within susceptible region 12q13 of simple congenital heart disease.  |  Gong, LG., et al. 2005. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22: 497-501. PMID: 16215934
7. Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma.  |  Shen, LY., et al. 2017. Oncol Lett. 14: 4835-4840. PMID: 29085488
8. Evidence for an oncogenic role of HOXC6 in human non-small cell lung cancer.  |  Yang, Y., et al. 2019. PeerJ. 7: e6629. PMID: 30993034
9. HOXC6 in the prognosis of prostate cancer.  |  Zhou, J., et al. 2019. Artif Cells Nanomed Biotechnol. 47: 2715-2720. PMID: 31271305
10. HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas.  |  Huang, H., et al. 2022. Cancer Cell Int. 22: 170. PMID: 35488304
11. High expression of HOXC6 predicts a poor prognosis and induces proliferation and inflammation in multiple myeloma cells.  |  Li, Z., et al. 2023. Genes Genomics. 45: 945-955. PMID: 37202556
12. HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation.  |  Weng, M., et al. 2024. Heliyon. 10: e23500. PMID: 38192826

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HoxC6 Antibody (B-7) has 15 citations in a variety of scientific publications.

Primary antibodies like Anti-HoxC6 Antibody (B-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HoxC6 Antibody (B-7) Specifications

Alternate Product Name: HoxC6

Product Clone Name: B-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 1-120

Epitope Target: HoxC6

Epitope Species: human

Product Reactivity/Detection: HoxC6 isoform 1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 15 citations in various scientific publications

Available Conjugates/Forms for HoxC6 Antibody (B-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin, X: TransCruz Reagent